Centrally acting antiemetics mitigate nausea and vomiting in patients with Alzheimer's disease who receive rivastigmine.
Jhee
Stanford S
SS
Shiovitz
Thomas
T
Hartman
Richard D
RD
Messina
John
J
Anand
Ravi
R
Sramek
John
J
Cutler
Neal R
NR
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy*; D000932:Antiemetics / Q000627:therapeutic use*; D002219:Carbamates / Q000009:adverse effects* / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D048448:Phenylcarbamates; D010865:Pilot Projects; D011446:Prospective Studies; D000068836:Rivastigmine; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
D000932:Antiemetics; D002219:Carbamates; D002800:Cholinesterase Inhibitors; D048448:Phenylcarbamates; D000068836:Rivastigmine